Telescope Innovations to Deliver First Self-Driving Lab for Korea's Largest Biopharma Manufacturers Association
Telescope Innovations (OTCQB: TELIF) announced that Korea's Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) has purchased a Self-Driving Lab (SDL) to be installed at a new R&D facility in Seoul within weeks (announcement dated November 17, 2025).
The SDL will form the core of KPBMA's first AI-driven training hub under the Convergence AI Institute for Drug Discovery (CAIID), supporting automation, education, and upskilling across KPBMA's 300 member companies. Telescope said the SDL uses robotics, inline analytics, and AI to run continuous closed-loop experiments that can accelerate iterative R&D and shorten development timelines. Telescope and KPBMA plan a strategic partnership to deploy and promote SDL adoption across Korea and the wider Asian market.
Telescope Innovations (OTCQB: TELIF) ha annunciato che l'Associazione dei Produttori Farmaceutici e Biotecnologici della Corea (KPBMA) ha acquistato un Laboratorio Autonomo (Self-Driving Lab, SDL) da installare in una nuova struttura di Ricerca e Sviluppo a Seul entro poche settimane (annuncio datato 17 novembre 2025).
Il SDL costituirà il nucleo del primo hub di formazione guidato dall'IA di KPBMA, nell'ambito dell'Convergence AI Institute for Drug Discovery (CAIID), supportando automazione, formazione e upskilling tra le 300 aziende associate. Telescope ha dichiarato che il SDL utilizza robotica, analisi in linea e IA per condurre esperimenti chiusi in loop continui che possono accelerare la R&S iterativa e abbreviare i tempi di sviluppo. Telescope e KPBMA pianificano una partnership strategica per implementare e promuovere l'adozione del SDL in Corea e nel mercato asiatico più ampio.
Telescope Innovations (OTCQB: TELIF) anunció que la Asociación de Fabricantes Farmacéuticos y Biofarmacéuticos de Corea (KPBMA) ha adquirido un Laboratorio Autónomo (SDL) para instalarse en una nueva instalación de I+D en Seúl en las próximas semanas (anuncio fechado el 17 de noviembre de 2025).
El SDL formará el centro de la primera incubadora de IA de KPBMA bajo el Convergence AI Institute for Drug Discovery (CAIID), apoyando la automatización, la educación y las habilidades a través de las 300 empresas asociadas. Telescope afirmó que el SDL utiliza robótica, analítica en línea e IA para ejecutar experimentos cerrados en bucle continuo que pueden acelerar la I+D iterativa y acortar los plazos de desarrollo. Telescope y KPBMA planean una asociación estratégica para desplegar y promover la adopción del SDL en Corea y en el mercado asiático más amplio.
Telescope Innovations (OTCQB: TELIF)가 한국의 제약 및 생물의약품 제조사 협회(KPBMA)가 자율 실험실을 구입해 서울의 새로운 연구개발 시설에 수 주 내 설치될 예정이라고 발표했습니다(공고일 2025년 11월 17일).
SDL은 CAIID(Convergence AI Institute for Drug Discovery) 아래 KPBMA의 첫 AI 기반 교육 허브의 핵심이 되어 자동화, 교육 및 역량강화를 지원합니다. KPBMA의 300개 회원사에 걸쳐 제공됩니다. SDL은 로봇공학, 인라인 분석 및 AI를 활용해 연속적으로 폐루프 실험을 수행하고 반복 연구개발을 가속화하며 개발 기간을 단축할 수 있다고 말했습니다. Telescope와 KPBMA는 SDL 도입을 한국 전역 및 wider 아시아 시장에 배치하고 촉진하기 위한 전략적 파트너십을 계획합니다.
Telescope Innovations (OTCQB: TELIF) a annoncé que l'Association coréenne des fabricants pharmaceutiques et biopharmaceutiques (KPBMA) a acquis un Laboratoire auto-guidé (Self-Driving Lab, SDL) qui sera installé dans une nouvelle installation de R&D à Séoul dans les prochaines semaines (annonce datée du 17 novembre 2025).
Le SDL formera le cœur du premier centre de formation piloté par l'IA de KPBMA, sous le Convergence AI Institute for Drug Discovery (CAIID), soutenant l'automatisation, l'éducation et le perfectionnement des compétences à travers les 300 sociétés membres. Telescope a déclaré que le SDL utilise la robotique, l'analytique en ligne et l'IA pour mener des expériences en boucle fermée continues qui peuvent accélérer la R&D itérative et raccourcir les délais de développement. Telescope et KPBMA planifient un partenariat stratégique pour déployer et promouvoir l'adoption du SDL en Corée et sur le marché asiatique plus large.
Telescope Innovations (OTCQB: TELIF) gab bekannt, dass der koreanische Verband der Pharma- und Biopharma-Hersteller (KPBMA) einen Self-Driving Lab (SDL) erworben hat, der in einer neuen F&E-Einrichtung in Seoul innerhalb weniger Wochen installiert wird (Verlautbarung vom 17. November 2025).
Das SDL wird den Kern des ersten KI-gesteuerten Ausbildungszentrums von KPBMA unter dem Convergence AI Institute for Drug Discovery (CAIID) bilden und Automatisierung, Bildung und Upskilling über die 300 Mitgliedsunternehmen hinweg unterstützen. Telescope sagte, das SDL nutze Robotik, Inline-Analytik und KI, um kontinuierliche Closed-Loop-Experimente zu betreiben, die iterative F&E beschleunigen und die Entwicklungszeiträume verkürzen können. Telescope und KPBMA planen eine strategische Partnerschaft, um die SDL-Einführung in Korea und auf dem breiteren asiatischen Markt zu fördern und umzusetzen.
Telescope Innovations (OTCQB: TELIF) أعلنت أن الجمعية الكورية لصناعي الأدوية والمُنتجين البيوفي (KPBMA) قد اشترت مختبر القيادة الذاتية (Self-Driving Lab, SDL) ليُثبت في منشأة بحث وتطوير جديدة في سيئول خلال أسابيع (الإعلان بتاريخ 17 نوفمبر 2025).
سيشكل SDL لبنة أساسية في أول مركز تدريب مدفوع بالذكاء الاصطناعي تحت مؤسسة Convergence AI Institute for Drug Discovery (CAIID)، وهو يدعم التشغيل الآلي والتعليم وتطوير المهارات عبر شركات KPBMA الـ 300 عضو. قالت Telescope إن SDL يستخدم الروبوتات، والتحليلات inline، والذكاء الاصطناعي لإجراء تجارب مغلقة حلقة مستمرة يمكن أن تسرع البحث والتطوير الدوري وتقلص أزمنة التطوير. تخطط Telescope وKPBMA لشراكة استراتيجية لنشر واعتماد SDL عبر كوريا والسوق الآسيوي الأوسع.
- KPBMA purchased Telescope SDL to be installed in Seoul within weeks
- KPBMA represents 300 member pharma and biotech companies
- Designation as Korea's first AI-driven SDL training hub (Nov 17, 2025)
- SDL platform designed for continuous closed-loop robotic experimentation
- None.
Korea's leading biopharma association selects Telescope's Self-Driving Lab to anchor the country's first AI-driven training hub
HIGHLIGHTS
- This installation for Korea's largest biopharma association represents the first Self-Driving Lab ("SDL") for drug development to be deployed in Korea
- Partnership supports Korea's transition toward automated and digital R&D
- SDL automates continuous experimental optimization using robotics, analytics, and AI
- SDLs show expanding commercial relevance across pharma, minerals, energy, agriculture, and chemicals industries.
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") today announces that the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association ("KPBMA") has purchased one of Telescope's Self-Driving Lab ("SDL") platforms to be installed at a brand-new R&D facility in Seoul in a matter of weeks. This groundbreaking facility aims to provide critical infrastructure to enable accelerated development of pharmaceuticals.
A Self-Driving Lab is an automated platform that uses robotics, inline analytics, and AI or machine-learning to run and optimize experiments in a continuous closed-loop workflow. Because it can operate continuously and adapt each experiment in real time, an SDL can complete and refine hundreds of experimental cycles far faster and with greater consistency than manual laboratory work. SDLs can dramatically accelerate iterative R&D, offering the potential to remove years from traditional development timelines and shorten the path from discovery to market-ready products. Telescope is recognized globally as one of the most advanced developers of Self-Driving Lab systems, with a uniquely integrated platform that enables true closed-loop, autonomous chemical experimentation.
Figure 1. A robotic element of Telescope's Self-Driving Lab.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8923/274498_89be634204169a49_001full.jpg
TELESCOPE SDL TO BE IMPLEMENTED AT THE FIRST AI-DRIVEN TRAINING HUB IN KOREA
KPBMA is the largest trade association of Korea's pharmaceutical and biotech industry, with 300 domestic and multinational member companies. Key elements of KPBMA's mission are to support R&D and foster innovation in pharmaceutical manufacturing. This year, KPBMA launched its first SDL initiative through its Convergence AI Institute for Drug Discovery (CAIID) to promote automation and AI-driven experimentation. Telescope's SDLs will form part of the training hub to demonstrate innovative infrastructure, provide education, and upskill researchers to fully capitalize on this new R&D method. Telescope is installing the SDL over the next few weeks, beyond which Telescope and KPBMA are building a strategic partnership for SDL deployment and adoption in Korea's pharmaceutical sector.
"We anticipate that this Self-Driving Lab will bring significant innovation to new drug development processes in Korea," commented Junhee Pyo, CAIID Vice Chief. "We also look forward to active global collaboration to facilitate technological exchange in this rapidly advancing field."
"Delivering our first Self-Driving Lab in South Korea will mark a major milestone for Telescope's intelligent automation technology, and for globally shifting the way pharmaceutical R&D is done," said Jason Hein, Telescope CTO. "We're excited to be working closely with KPBMA and CAIID under their SDL initiative, and look forward to leading the deployment and adoption of SDLs in Asia."
"Asia represents one of the fastest-growing markets for lab automation and the digital R&D transformation," said Henry Dubina, Telescope CEO. "Partnering with KPBMA on Korea's first AI-driven SDL hub positions Telescope at the center of this momentum. We see this as the foundation for broader regional adoption of SDLs across research institutes and biopharma companies seeking faster, data-driven development."
BROADER COMMERCIAL OPPORTUNITY FOR SDLs
Self-Driving Labs represent a platform technology gaining strong momentum in pharmaceutical R&D, and importantly they also offer growing applicability across agriculture, minerals and natural resources, energy, and the chemical industries. Their autonomous, adaptive operation makes SDLs effective in remote or high-risk environments where conventional laboratory workflows are difficult to maintain.
About Telescope Innovations
Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: henry.dubina@telescopeinn.com
Forward-Looking Information
Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.
Forward-looking statements in this document include statements regarding the anticipated installation, commissioning, and operation of Telescope's Self-Driving Lab ("SDL") in Korea; the timing, scope, and outcomes of the Company's collaboration with the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association ("KPBMA") and its Convergence AI Institute for Drug Discovery ("CAIID"); the potential for future SDL deployments or adoption in Korea and other Asian markets, and other markets across agriculture, minerals, energy, and chemicals; the expected benefits of Telescope's automation technologies in accelerating pharmaceutical research and development, and all other statements that are not statements of historical fact.
The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274498
FAQ
What did Telescope (TELIF) announce on November 17, 2025 about Korea?
Who is the buyer of Telescope's SDL and how many members does it represent?
When will Telescope install the SDL for KPBMA and where?
What capabilities does Telescope's Self-Driving Lab offer for drug R&D?
How will the KPBMA SDL be used by Korea's pharmaceutical sector?
Does the announcement disclose commercial terms or financial impact for TELIF shareholders?
